Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News

ETF Overview

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.

Key Stats

• Today's Range: $69.70 to $71.05
• 50-Day Range: $63.89 to $68.84
• 52-Week Range: $54.52 to $72.84
• Volume: 6,849 shs
• Average Volume: 8,381 shs
• Market Capitalization: $243.86 million
• Assets Under Management: $218.41 million
• Dividend Yield: 0.23%
• Net Expense Ratio: 0.58%
• Aggregate Rating: Moderate Buy

PBE ETF - Frequently Asked Questions

How have PBE shares performed this year?

Invesco Biotechnology & Genome ETF's stock was trading at $66.53 at the start of the year. Since then, PBE stock has increased by 6.3% and is now trading at $70.7310.

Who are Invesco Biotechnology & Genome ETF's major shareholders?

Top institutional investors of Invesco Biotechnology & Genome ETF include Gerber Kawasaki Wealth & Investment Management (7.37%), Bank of America Corp DE (1.69%), YHB Investment Advisors Inc. (0.70%) and Cetera Investment Advisers (0.59%).

How do I buy shares of Invesco Biotechnology & Genome ETF?

Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Invesco Biotechnology & Genome ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), Activision Blizzard (ATVI), NVIDIA (NVDA) and Bristol Myers Squibb (BMY).

Fund Details

• Issuer: Invesco
• Fund Name: Invesco Biotechnology & Genome ETF
• Tax Classification: Regulated Investment Company
• Stock Exchange: NYSEARCA
• Current Symbol: NYSEARCA:PBE
• Inception Date: 6/23/2005
• Fund Manager: Peter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser
• Web: www.invescopowershares.com
• Phone: +1-800-9830903

Fund Focus

• Asset Class: Equity
• Benchmark: Dynamic Biotech & Genome Intellidex Index
• Category: Sector
• Focus: Health Care
• Development Level: Developed Markets
• Region: North America
• Number of Holdings: 32

Fund Statistics

• Assets Under Management: $218.41 million
• Average Daily Volume: $16.59 thousand
• Discount/Premium: -0.02%

Administrator, Advisor and Custodian

• Administrator: The Bank of New York Mellon Corporation
• Advisor: Invesco Capital Management, LLC
• Custodian: The Bank of New York Mellon Corporation
• Distributor: Invesco Distributors, Inc.
• Transfer Agent: The Bank of New York Mellon Corporation
• Trustee: N/A
• Lead Market Maker: Citadel

Options

• Optionable: Optionable
• Options Volume: 1
• Put Options: 5
• Call Options: 1
• Short Interest: 600 shs

Miscellaneous

• Outstanding Shares: 3,450,000
• Beta: 0.87
• Creation Unit: 10,000
• Creation Fee: $500.00